Combining FOXM1 inhibitors with platinum based chemotherapeutic agents (cisplatin or carboplatin) might have a more drastic effect in aggressive SCLC cells as FOXM1 is known to confer chemoresistance in some other cancers [40]. The gene discussed is FOXM1; the disease is small cell lung carcinoma.